Drug Profile
BAY 1902607
Alternative Names: BAY-1902607Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Bayer
- Class Antitussives
- Mechanism of Action Purinergic P2X3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cough
Most Recent Events
- 07 Sep 2020 Interim efficacy and adverse events data from a phase I/II trial in Cough presented at the 30th Annual Congress of the European Respiratory Society (ERS-2020)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Cough(In volunteers) in Germany (PO, Tablet)
- 01 Feb 2020 Discontinued - Phase-I for Cough (In volunteers) in Germany (PO)